Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Payables (2021 - 2025)

Historic Payables for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $49.8 million.

  • ARS Pharmaceuticals' Payables rose 20124.08% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.8 million, marking a year-over-year increase of 20124.08%. This contributed to the annual value of $22.8 million for FY2024, which is 96039.93% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Payables is $49.8 million, which was up 20124.08% from $44.3 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Payables high stood at $49.8 million for Q3 2025, and its period low was $126000.0 during Q3 2022.
  • For the 5-year period, ARS Pharmaceuticals' Payables averaged around $12.0 million, with its median value being $6.6 million (2024).
  • As far as peak fluctuations go, ARS Pharmaceuticals' Payables crashed by 9267.44% in 2022, and later surged by 858650.79% in 2023.
  • ARS Pharmaceuticals' Payables (Quarter) stood at $6.6 million in 2021, then dropped by 25.13% to $4.9 million in 2022, then plummeted by 56.32% to $2.2 million in 2023, then soared by 960.4% to $22.8 million in 2024, then skyrocketed by 117.89% to $49.8 million in 2025.
  • Its last three reported values are $49.8 million in Q3 2025, $44.3 million for Q2 2025, and $27.0 million during Q1 2025.